The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase I/II study of LAG525 ± spartalizumab (PDR001) in patients (pts) with advanced malignancies.
 
David S. Hong
Stock and Other Ownership Interests - MolecularMatch; Oncorena
Honoraria - Adaptimmune; Baxter; Bayer; Merrimack
Consulting or Advisory Role - Baxter; Bayer; Guidepoint Global; Janssen
Research Funding - Abbvie; Adaptimmune; Amgen; AstraZeneca; Bayer; Bristol-Myers Squibb; Daiichi Sankyo; Eisai; Genentech; Genmab; Ignyta; Infinity Pharmaceuticals; Kite, a Gilead company; Kyowa Hakko Kirin; Lilly; Loxo; MedImmune; Merck; Mirati Therapeutics; miRNA Therapeutics; Molecular Templates; Novartis; Pfizer; Takeda
Travel, Accommodations, Expenses - Loxo; miRNA Therapeutics
Other Relationship - Oncorena
 
Patrick Schoffski
Consulting or Advisory Role - Blueprint Medicines (Inst); Eisai (Inst); Ellipses Pharma (Inst); Epizyme (Inst); Ipsen (Inst); Lilly (Inst); Loxo (Inst); Piqur (Inst); Plexxikon (Inst)
Research Funding - Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); CoBioRes NV (Inst); Eisai (Inst); Exelixis (Inst); G1 Therapeutics (Inst); Lilly (Inst); Novartis (Inst); PharmaMar (Inst); Plexxikon (Inst)
 
Aitana Calvo
Research Funding - Bayer; Novartis; SERVIER
Expert Testimony - Amgen; BioSim; Merck; Sanofi
 
John Sarantopoulos
Consulting or Advisory Role - Amgen; AstraZeneca/MedImmune; Bayer; Bristol-Myers Squibb; Eisai; Exelixis; Fulgent Genetics; Genentech/Roche; Merck; Novartis; Pfizer; Sun Pharma; Takeda
 
María Ochoa De Olza
No Relationships to Disclose
 
Richard D. Carvajal
Consulting or Advisory Role - AstraZeneca; Aura Biosciences; Bristol-Myers Squibb; Castle Biosciences; Genentech/Roche; Iconic Therapeutics; Janssen Oncology; Merck; Novartis
 
Amy Prawira
Research Funding - Akeso Biopharma (Inst); Bayer (Inst); BeiGene (Inst); Bristol-Myers Squibb (Inst); CStone Pharmaceuticals (Inst); Hutchison MediPharma (Inst); Lilly (Inst); Macrogenics (Inst); Merck (Inst); Pfizer (Inst); Roche/Genentech (Inst)
 
Chrisann Kyi
No Relationships to Disclose
 
Taito Esaki
Honoraria - Kyowa Hakko Kirin; Lilly
Consulting or Advisory Role - Chugai Pharma
Speakers' Bureau - Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo; Eisai; Lilly; Merck Serono; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda
Research Funding - Daiichi Sankyo (Inst); Dainippon Sumitomo Pharma (Inst); Merck Serono (Inst); MSD (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)
 
Wallace L. Akerley
Honoraria - AstraZeneca
Consulting or Advisory Role - AstraZeneca
Speakers' Bureau - Bristol-Myers Squibb
Travel, Accommodations, Expenses - AstraZeneca
 
Filippo G. De Braud
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Celgene; Daiichi Sankyo; Dompè; Ignyta; Novartis; Pfizer; SERVIER; Tiziana Life Sciences
Speakers' Bureau - Bristol-Myers Squibb; Lilly; Menarini; MSD; Novartis; Pfizer; Roche; SERVIER
Research Funding - Amgen (Inst); Bristol-Myers Squibb (Inst); Ignyta (Inst); Lilly (Inst); MedImmune (Inst); Merck Serono (Inst); MSD (Inst); Nektar; Novartis (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Amgen; Bristol-Myers Squibb; Roche
 
Rina Hui
Honoraria - AstraZeneca; Bristol-Myers Squibb; Merck Sharp & Dohme; Novartis
Consulting or Advisory Role - AstraZeneca; Merck Sharp & Dohme; Novartis; Roche
Travel, Accommodations, Expenses - Roche
 
Tian Zhang
Leadership - Capio BioSciences (I)
Stock and Other Ownership Interests - Capio Biosciences (I)
Consulting or Advisory Role - AstraZeneca; Bayer; Exelixis; G1 Therapeutics; Genentech/Roche; Janssen; Sanofi
Speakers' Bureau - Exelixis
Research Funding - Acerta Pharma (Inst); Janssen (Inst); Merrimack (Inst); Novartis (Inst); OmniSeq (Inst); Personal Genome Diagnostics (Inst); Pfizer (Inst); Stem CentRx (Inst)
Patents, Royalties, Other Intellectual Property - Circulating tumor cell novel capture by c-MET technology (Inst)
Travel, Accommodations, Expenses - Acerta Pharma
 
Ross A. Soo
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Lilly; Merck Sharp & Dohme; Novartis; Pfizer; Roche/Genentech
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Merck Sharp & Dohme; Novartis; Pfizer; Roche/Genentech; Taiho Pharmaceutical
Research Funding - AstraZeneca
 
Michela Maur
Travel, Accommodations, Expenses - Astellas Oncology
 
Andrew James Weickhardt
Honoraria - Eisai; Ipsen
Speakers' Bureau - Astellas Pharma
Research Funding - Merck
Travel, Accommodations, Expenses - Astellas Pharma; Ipsen
 
Niladri Roy Chowdhury
Employment - Novartis
 
Catherine Sabatos-Peyton
Employment - Novartis
Stock and Other Ownership Interests - Novartis
Patents, Royalties, Other Intellectual Property - Novartis
 
Eunice Lee Kwak
Research Funding - Sanofi (Inst)
Travel, Accommodations, Expenses - Amgen
 
Daniel Shao-Weng Tan
Consulting or Advisory Role - Celgene; Loxo; Merck; Novartis
Research Funding - GlaxoSmithKline (Inst); Novartis
Travel, Accommodations, Expenses - Boehringer Ingelheim; Pfizer